Core Insights - Edgewise Therapeutics, Inc. has appointed Christopher Martin, a biotechnology veteran, to its Board of Directors, enhancing its leadership team as it prepares for significant product launches [1][2][3] Company Overview - Edgewise Therapeutics is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions, with a strong emphasis on muscle physiology [4] - The company is advancing its lead product, Sevasemten, which is in late-stage clinical trials for Becker and Duchenne muscular dystrophies, and is also developing EDG-7500 and EDG-15400 for cardiac conditions [4] Leadership Background - Christopher Martin previously served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October 2025, and has extensive experience in building commercial organizations and launch strategies [3] - His past roles include Executive Director of Marketing at SK Life Science and Head of Marketing at Cempra, where he led the development and launch strategies for multiple products [3]

Financial Performance - Bausch Health (excl B+L) achieved its 10th consecutive quarter of revenue and Adjusted EBITDA growth[18] - BHC (Excl B+L) reported revenue growth of 7% and organic revenue growth of 5% in 3Q25, reaching $1400 million[20] - BHC (Excl B+L) Adjusted EBITDA increased by 7% in 3Q25, including an $81 million Acquired IPR&D charge, reaching $773 million[21] - Consolidated revenue increased by 7% to $2681 million in 3Q25, with organic growth of 5%[26, 27] - Adjusted EBITDA attributable to Bausch Health Companies Inc increased by 8% to $986 million in 3Q25[27] - Adjusted Cash Flow from Operations was $508 million[27] Segment Performance - Salix segment reported revenue of $716 million, a 12% increase, with Xifaxan contributing significantly to growth[41, 42] - Solta Medical segment revenue increased by 25% to $140 million, driven by volume expansion across all geographies[55, 56] - Bausch + Lomb reported revenue of $1281 million, a 7% increase, with single-digit growth across all business segments[67] Guidance - The company raised its full-year 2025 Adjusted Operating Cash Flow guidance for Bausch Health (Excl B+L) to $0975 - $1025 billion[74]

2Q 2025 Earnings July 30, 2025 forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward- looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or r ...